Display options
Share it on

Immune Netw. 2017 Aug;17(4):214-227. doi: 10.4110/in.2017.17.4.214. Epub 2017 Aug 09.

Cytokine Signaling in Tumor Progression.

Immune network

Myungmi Lee, Inmoo Rhee

Affiliations

  1. Department of Bioscience and Biotechnology, Sejong University, Seoul 05006, Korea.

PMID: 28860951 PMCID: PMC5577299 DOI: 10.4110/in.2017.17.4.214

Abstract

Cytokines are molecules that play critical roles in the regulation of a wide range of normal functions leading to cellular proliferation, differentiation and survival, as well as in specialized cellular functions enabling host resistance to pathogens. Cytokines released in response to infection, inflammation or immunity can also inhibit cancer development and progression. The predominant intracellular signaling pathway triggered by cytokines is the JAK-signal transducer and activator of transcription (STAT) pathway. Knockout mice and clinical human studies have provided evidence that JAK-STAT proteins regulate the immune system, and maintain immune tolerance and tumor surveillance. Moreover, aberrant activation of the JAK-STAT pathways plays an undeniable pathogenic role in several types of human cancers. Thus, in combination, these observations indicate that the JAK-STAT proteins are promising targets for cancer therapy in humans. The data supporting this view are reviewed herein.

Keywords: Cancer; Cytokine; JAK-STAT; Kinase inhibitor

Conflict of interest statement

Conflict of Interest: The authors declare no potential conflicts of interest.

References

  1. Mol Cancer Res. 2010 Jan;8(1):35-45 - PubMed
  2. Prostate. 2002 Jun 1;51(4):241-6 - PubMed
  3. Br J Pharmacol. 2005 Jul;145(6):818-28 - PubMed
  4. J Oral Pathol Med. 2016 Dec 15;:null - PubMed
  5. Exp Hematol. 2011 Jan;39(1):95-101 - PubMed
  6. Blood. 2002 Mar 1;99(5):1758-65 - PubMed
  7. Oncogene. 2001 Feb 15;20(7):849-58 - PubMed
  8. Clin Cancer Res. 1998 Jun;4(6):1405-14 - PubMed
  9. N Engl J Med. 2010 Sep 16;363(12):1117-27 - PubMed
  10. Nat Biotechnol. 2012 Jan 09;30(1):3-5 - PubMed
  11. Oncol Rep. 2017 Jan;37(1):83-90 - PubMed
  12. Clin Cancer Res. 2008 Jun 15;14 (12 ):3716-21 - PubMed
  13. Blood. 2006 Nov 15;108(10):3262-70 - PubMed
  14. PLoS One. 2017 Jan 31;12 (1):e0171169 - PubMed
  15. Blood. 2011 Feb 10;117(6):1938-46 - PubMed
  16. Immunity. 2007 May;26(5):535; author reply 536 - PubMed
  17. Leuk Lymphoma. 2008 Mar;49(3):388-97 - PubMed
  18. Annu Rev Med. 2015;66:311-28 - PubMed
  19. Haematologica. 2012 Dec;97(12):1895-903 - PubMed
  20. Nat Genet. 2009 Apr;41(4):455-9 - PubMed
  21. Oncogene. 2000 Nov 20;19(49):5662-79 - PubMed
  22. Nat Struct Mol Biol. 2012 Aug;19(8):754-9 - PubMed
  23. PLoS One. 2011 Apr 20;6(4):e18856 - PubMed
  24. Annu Rev Immunol. 1998;16:293-322 - PubMed
  25. Leuk Lymphoma. 2015;56(9):2543-51 - PubMed
  26. Annu Rev Immunol. 2015;33:139-67 - PubMed
  27. Mol Cell Biol. 2001 Jan;21(2):678-89 - PubMed
  28. Proc Natl Acad Sci U S A. 2000 Apr 11;97(8):4227-32 - PubMed
  29. Proc Natl Acad Sci U S A. 2015 Oct 6;112(40):12480-5 - PubMed
  30. Cancer Res. 2016 Mar 1;76(5):1031-43 - PubMed
  31. Blood Cancer J. 2011 Nov;1(11):e44 - PubMed
  32. Acta Haematol. 2008;119(1):38-9 - PubMed
  33. ACS Chem Biol. 2016 Dec 16;11(12 ):3442-3451 - PubMed
  34. Leuk Res. 2014 Mar;38(3):316-22 - PubMed
  35. J Clin Oncol. 2011 Mar 1;29(7):789-96 - PubMed
  36. Blood. 2006 Sep 15;108(6):1865-7 - PubMed
  37. Leukemia. 2006 Jan;20(1):182-5 - PubMed
  38. Blood. 2012 Jun 21;119(25):6089-98 - PubMed
  39. Am J Transplant. 2010 Aug;10(8):1785-95 - PubMed
  40. Blood. 2008 Feb 1;111(3):1686-9 - PubMed
  41. J Med Chem. 2014 Jun 26;57(12):5023-38 - PubMed
  42. Blood. 2008 Jun 15;111(12):5663-71 - PubMed
  43. Blood. 2002 Jan 15;99(2):680-9 - PubMed
  44. Leukemia. 2008 Apr;22(4):686-707 - PubMed
  45. Nature. 2001 Jan 18;409(6818):349-54 - PubMed
  46. Immune Netw. 2016 Apr;16(2):99-108 - PubMed
  47. Mol Cell. 2000 Sep;6(3):693-704 - PubMed
  48. Nat Rev Cancer. 2004 Feb;4(2):97-105 - PubMed
  49. Blood. 2008 Feb 15;111(4):2155-7 - PubMed
  50. Gene. 2002 Feb 20;285(1-2):1-24 - PubMed
  51. Cancer Chemother Pharmacol. 2011 Oct;68(4):1057-65 - PubMed
  52. N Engl J Med. 2005 Apr 28;352(17):1779-90 - PubMed
  53. Blood. 2014 Oct 9;124(15):2463 - PubMed
  54. Cancer Res. 2008 Sep 1;68(17):6884-8 - PubMed
  55. Gastroenterology. 2008 Feb;134(2):379 - PubMed
  56. Leukemia. 2016 Jan;30(1):94-103 - PubMed
  57. Mol Cell Biol. 1995 Dec;15(12 ):7050-8 - PubMed
  58. J Immunother. 2010 Nov-Dec;33(9):991-8 - PubMed
  59. Cancer Res. 2009 Feb 1;69(3):1009-15 - PubMed
  60. Cell Cycle. 2004 Dec;3(12):1486-8 - PubMed
  61. J Biomol Struct Dyn. 2015;33(11):2368-79 - PubMed
  62. JAKSTAT. 2012 Jul 1;1(3):184-90 - PubMed
  63. Oncogene. 2013 May 23;32(21):2601-13 - PubMed
  64. J Clin Pharmacol. 2012 Jun;52(6):809-18 - PubMed
  65. Blood Cancer J. 2015 Oct 02;5:e351 - PubMed
  66. Chem Biol. 2005 Apr;12(4):407-8 - PubMed
  67. Immunity. 2010 May 28;32(5):605-15 - PubMed
  68. Cancer Res. 2002 Jun 15;62(12):3351-5 - PubMed
  69. Trends Biochem Sci. 2008 Mar;33(3):122-31 - PubMed
  70. Cancer Cell. 2009 Aug 4;16(2):91-102 - PubMed
  71. N Engl J Med. 2013 Jan 10;368(2):161-70 - PubMed
  72. Curr Cancer Drug Targets. 2009 Sep;9(6):738-47 - PubMed
  73. Int Immunopharmacol. 2011 Jul;11(7):856-61 - PubMed
  74. Proc Natl Acad Sci U S A. 2006 Nov 7;103(45):16930-5 - PubMed
  75. Nature. 2008 Jul 24;454(7203):436-44 - PubMed
  76. Blood. 2006 Aug 15;108(4):1377-80 - PubMed
  77. Blood. 2004 Dec 1;104(12):3712-21 - PubMed
  78. Blood. 2005 Aug 15;106(4):1207-9 - PubMed
  79. Cancer Res. 2009 Sep 1;69(17):6823-30 - PubMed
  80. Immunity. 2012 Apr 20;36(4):515-28 - PubMed
  81. Cancer Cell. 2008 Apr;13(4):321-30 - PubMed
  82. Oncotarget. 2015;6(12):9807-19 - PubMed
  83. Cancer Sci. 2014 Aug;105(8):1071-8 - PubMed
  84. Leukemia. 2017 May 05;:null - PubMed
  85. Semin Thromb Hemost. 2006 Jun;32(4 Pt 2):341-51 - PubMed
  86. Blood. 2007 May 1;109(9):3972-81 - PubMed

Publication Types